Novartis AG (XTER:NOT) Cyclically Adjusted Revenue per Share: €23.13 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:NOT Novartis AG XTER:NOT
78 GF Score
Price €134.60
GF Value €112.40
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Novartis AG Cyclically Adjusted Revenue per Share?

Novartis AG XTER:NOT 78 Cyclically Adjusted Revenue per Share is €23.13 as of Mar. 2026. GuruFocus rates XTER:NOT with a GF Score™ of 78/100 and a GF Value™ of €112.40 (Modestly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Novartis AG's adjusted revenue per share for the three months ended in Mar. 2026 was €6.106. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €23.13 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Novartis AG's average Cyclically Adjusted Revenue Growth Rate was 1.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 1.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 1.30% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 0.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Novartis AG was 4.30% per year. The lowest was -0.90% per year. And the median was 1.15% per year.

As of today (2026-07-14), Novartis AG's current stock price is €134.60. Novartis AG's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €23.13. Novartis AG's Cyclically Adjusted PS Ratio of today is 5.82.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Novartis AG was 6.18. The lowest was 2.83. And the median was 3.87.


Novartis AG  (XTER:NOT) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Novartis AG's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=134.60/23.13
=5.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Novartis AG was 6.18. The lowest was 2.83. And the median was 3.87.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Novartis AG Cyclically Adjusted Revenue per Share Related Terms


Novartis AG Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Novartis AG's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis AG Cyclically Adjusted Revenue per Share Chart

Novartis AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.93 20.69 19.54 18.91 22.77

Novartis AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.31 22.69 22.43 22.77 23.13

XTER:NOT vs LLY, JNJ, ABBV: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Novartis AG's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis AG Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Novartis AG's Cyclically Adjusted PS Ratio falls into.


XTER:NOT
78GF Score
Novartis AG XTER:NOT
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novartis AG Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novartis AG's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=6.106/108.0600*108.0600
=6.106

Current CPI (Mar. 2026) = 108.0600.

Novartis AG Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 4.700 100.088 5.074
201609 4.580 99.604 4.969
201612 4.992 99.380 5.428
201703 4.612 100.040 4.982
201706 4.686 100.285 5.049
201709 4.514 100.254 4.865
201712 2.304 100.213 2.484
201803 3.857 100.836 4.133
201806 4.252 101.435 4.530
201809 4.174 101.246 4.455
201812 4.467 100.906 4.784
201903 4.334 101.571 4.611
201906 4.561 102.044 4.830
201909 4.934 101.396 5.258
201912 4.961 101.063 5.304
202003 5.018 101.048 5.366
202006 4.479 100.743 4.804
202009 4.624 100.585 4.968
202012 4.689 100.241 5.055
202103 4.708 100.800 5.047
202106 4.887 101.352 5.210
202109 5.041 101.533 5.365
202112 1.811 101.776 1.923
202203 5.201 103.205 5.446
202206 5.599 104.783 5.774
202209 4.996 104.835 5.150
202212 4.797 104.666 4.953
202303 4.867 106.245 4.950
202306 5.175 106.576 5.247
202309 5.460 106.570 5.536
202312 5.207 106.461 5.285
202403 5.423 107.355 5.459
202406 5.845 107.991 5.849
202409 5.855 107.468 5.887
202412 6.448 107.128 6.504
202503 6.366 107.722 6.386
202506 6.563 108.075 6.562
202509 6.306 107.710 6.326
202512 6.111 107.200 6.160
202603 6.106 108.060 6.106

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €23.13 mean?
Novartis AG (XTER:NOT) has a Cyclically Adjusted Revenue per Share of €23.13 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Novartis AG and its competitors.
Is Novartis AG's Cyclically Adjusted Revenue per Share too high?
Novartis AG's current Cyclically Adjusted Revenue per Share is €23.13. Overall, Novartis AG has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novartis AG's Cyclically Adjusted Revenue per Share compare to LLY and JNJ?
Novartis AG's Cyclically Adjusted Revenue per Share of €23.13 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Novartis AG and its competitors. Novartis AG's current Cyclically Adjusted Revenue per Share is €23.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis AG stock overvalued right now?
Based on GuruFocus' analysis, Novartis AG (XTER:NOT) is currently considered Modestly Overvalued. The stock's GF Value™ is €112.40, compared to a current price of €134.60 — trading 19.8% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €23.13. Novartis AG's overall GF Score™ is 78/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Novartis AG (XTER:NOT), the current Cyclically Adjusted Revenue per Share is €23.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novartis AG (XTER:NOT) Overvalued in 2026?

Based on GuruFocus' analysis, Novartis AG stock appears to be overvalued. The current stock price of €134.60 is trading 19.8% above its estimated GF Value™ of €112.40. GuruFocus considers Novartis AG to be Modestly Overvalued.

Key valuation signals for XTER:NOT:

  • Cyclically Adjusted Revenue per Share: €23.13
  • GF Value™: €112.40 vs. price of €134.60 (19.8% above fair value)
  • GF Score™: 78/100 with 7 warning signs

No single metric tells the full story. See the XTER:NOT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novartis AG Business Description

Address Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
78GF Score

Get the complete analysis for XTER:NOT

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€134.60
Price
€112.40
GF Value